Skip to main content
main-content

Lung cancer: Immunotherapy

Journal articles and book chapters

13-09-2019 | Small-cell lung cancer | Video | Article

Expert comment: CASPIAN trial of durvalumab in SCLC

WATCH | Raffaele Califano comments on the CASPIAN trial of front-line durvalumab plus chemotherapy in extensive-stage small-cell lung cancer, and puts the findings in context of the IMpower133 study of atezolizumab in the same setting (3:30).

09-09-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: TMB not prognostic for KEYNOTE-189 participant outcomes

WATCH | Marina Garassino reports the KEYNOTE-189 tumor mutational burden analysis and what the findings mean for this biomarker (4:03).

09-09-2019 | Non-small cell lung cancer | WCLC 2019 | Article

Researcher comment: CheckMate 817 trial of nivolumab–ipilimumab

WATCH | Is first-line nivolumab–ipilimumab a feasible option for certain subgroups of advanced non-small-cell lung cancer patients, such as those with poor functional status? Fabrice Barlesi discusses the CheckMate 817 trial (3:32).

08-09-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: TMB does not predict NSCLC pembrolizumab–chemotherapy response

WATCH | Corey Langer describes the findings from the KEYNOTE-021 exploratory analysis of the relationship between response to pembrolizumab plus chemotherapy and tumor mutational burden in metastatic non-small-cell lung cancer patients (7:35).

08-09-2019 | Lung cancer | Video | Article

Expert highlights from WCLC 2019

WATCH | Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).

17-06-2019 | Small-cell lung cancer | Article

Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential

Armstrong SA & Liu SV. Adv Ther 2019. doi:10.1007/s12325-019-01008-2

04-06-2019 | Non-small cell lung cancer | ASCO 2019 | Article

Expert comment: 5-year update of KEYNOTE-001

ASCO expert David Graham tells us just why he thinks the 5-year survival data from the advanced non-small-cell lung cancer patients enrolled in the phase Ib KEYNOTE-001 trial are so remarkable (1:26).

03-06-2019 | Non-small cell lung cancer | ASCO 2019 | Article

Researcher comment: 5-year KEYNOTE-001 results show long-lasting survival for some advanced NSCLC patients

Edward Garon presents the 5-year follow-up results of the advanced non-small-cell lung cancer cohort of the phase I KEYNOTE-001 trial of pembrolizumab monotherapy (4:12).

01-04-2019 | Malignant pleural disease | Video | Article

Researcher comment: CAR T-cell therapy for malignant pleural disease

Prasad Adusumilli outlines the key results of their phase I trial showing promising safety and efficacy of a mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease, and also discusses the next steps (4:09).

04-02-2019 | Non-small cell lung cancer | Article

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

Camidge DR et al. Nat Rev Clin Oncol 2019; 16(6): 341-355. doi:10.1038/s41571-019-0173-9.

12-12-2018 | Immunotherapy | Feature | Article

Hyperprogression as a response to immunotherapy: ‘A serious downside’

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

10-05-2018 | Non-small cell lung cancer | Article

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Leonardi GC et al. J Clin Oncol 2018; 36(19): 1905-1912. doi:10.1200/JCO.2017.77.0305

16-04-2018 | Lung cancer | Article

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde PA et al. N Eng J Med 2018. doi:10.1056/NEJMoa1716078

16-04-2018 | Non-small cell lung cancer | Article

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Hellmann MD et al. N Eng J Med 2018. 10.1056/NEJMoa1801946

16-04-2018 | Pembrolizumab | Article

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Gandhi L et al. N Eng J Med 2018. 10.1056/NEJMoa1801005

10-04-2018 | Response criteria | Article

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour L et al. Lancet Oncol 2017; 18(3): e143–e152. doi:10.1016/S1470-2045(17)30074-8

12-03-2018 | Durvalumab | Article

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino MC et al. Lancet Oncol 2018; 19(4): 521–536. doi:10.1016/S1470-2045(18)30144-X

07-03-2018 | Immunotherapy | Article

Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management

Samaan MA et al. Nat Rev Gastroenterol Hepatol 2018; 15:222–234. doi:10.1038/nrgastro.2018.1

Image Credits